

Reimbursement Information for Pharmacists - Liraglutide 6 mg/ml solution for injection: Victoza® and Saxenda®

- ✓ Two preparations of liraglutide 6 mg/ml solution for injection are reimbursed under the Community Drug Schemes (CDS) [see Table 1 below] - Victoza® and Saxenda®.
- ✓ Important differences exist between both preparations- see Table 1 and Table 2 below. Refer to the individual SmPCs for full prescribing information.

Table 1: Product information for liraglutide 6 mg/ml solution for injection (Victoza® and Saxenda®)

Medicinal Product	Victoza®	Saxenda®
Reimbursed indication	Adults, Adolescents and Children aged 10 years & above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: <ul style="list-style-type: none"> • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. 	A subgroup of the full licensed indication is approved for reimbursement: <ul style="list-style-type: none"> • Adult patients, as an adjunct to a reduced-calorie diet and increased physical activity for weight management, with an initial body mass index of $\geq 35 \text{ kg/m}^2$ with prediabetes and high-risk of cardiovascular disease. Treatment should be discontinued for patients who have not lost $\geq 5\%$ of their initial body weight after 12 weeks of treatment at the 3.0 mg/day dose. <ul style="list-style-type: none"> • See SmPC for full prescribing information.
Presentation	2 and 3 pack	5 pack
Dose	Starting dose is 0.6 mg daily. After at least one week the dose should be increased to 1.2 mg. The dose can be further increased after at least one week to a maximum of 1.8 mg daily.	Starting dose is 0.6 mg daily. This dose should be increased in increments of 0.6 mg with at least one-week intervals to a maximum dose of 3.0 mg daily.
CDS	GMS and LTI schemes only.	GMS and DP schemes only.
Reimbursement application system (RAS)	No	Yes- See Medicines Management Programme (MMP) Managed Access Protocol (MAP) which can be accessed at www.hse.ie/yourmedicines . Total duration of reimbursement support is 2 years from the date of the Phase 1 application.
Quantity restrictions	Yes (as per maximum approved dose)	Yes (as per maximum approved dose)

CDS= Community Drug Schemes; DP= Drugs Payment; GMS= General Medical Services; LTI= Long Term Illness; MAP= Managed Access Protocol; MMP= Medicines Management Programme; RAS= Reimbursement Application System; SmPC= Summary of Product Characteristics

Table 2: Liraglutide 6 mg/ml (Victoza® and Saxenda®) solution for injection and appropriate monthly quantities to be dispensed for reimbursement under the CDS

Preparation	Pack size	Total daily dose	GMS code	Price*	Monthly dispensed quantity
Victoza® 6 mg/ml solution for injection in pre-filled pen	2 x 3 ml	1.2 mg	47980	€ 94.01	One box containing two pens per month should be dispensed for patients prescribed 1.2 mg daily.
	3 x 3 ml	1.8 mg	47981	€ 147.10	One box containing three pens per month should be dispensed for patients prescribed 1.8 mg daily.
Saxenda® 6 mg/ml solution for injection in pre-filled pen	5 x 3 ml	3.0 mg	37709	€ 186.98	One box containing five pens per month should be dispensed for patients prescribed 3.0 mg daily , with up to 13 packs supported annually for reimbursement.

*PCRS reimbursement price as of 03/01/2023; CDS= Community Drug Schemes.